Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 4/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.39 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845217 | 0.95 | ADRA1A (0.56) | ADRA1AL3MBTL3L3MBTL1BCHEKDM4E | |
| Trifluoroacetic Acid SCHEMBL18185657 | 0.88 | ADRA1A (0.66) | ADRA1AL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL16845189 | 0.83 | ADRA1A (0.72) | ADRA1AL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL16845192 | 0.75 | MEN1 (0.54) | ADRA1AL3MBTL3L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL18185636 | 0.74 | L3MBTL3 (0.51) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845173 | 0.74 | L3MBTL3 (0.51) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| Trifluoroacetic Acid SCHEMBL18185645 | 0.74 | ADRA2C (0.53) | ADRA1AL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL18185575 | 0.73 | ADRA1A (0.57) | ADRA1AL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL18185585 | 0.71 | ADRA1A (0.58) | ADRA1ABCHE | |
| SCHEMBL16823896 | 0.70 | ADRA1A (0.43) | ADRA1AL3MBTL3KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNI3, TNNC1, FABP3 | ADRA1A 1241/4885L3MBTL3 1001/4885L3MBTL1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.